Mei Ya-bo, Wang Ya-di, Liao Zhi-yong, Hao Wei, Che Xiao-yan
Central Laboratory, Zhujiang Hospital, The First Military Medical University, Guangzhou 510282, China.
Zhonghua Yi Xue Za Zhi. 2005 Mar 2;85(8):526-9.
To explore the laws of the appearance of the specific serum antibodies against the nucleocapsid (N) protein and the S1 domain of spike (S) glycoprotein in patients with severe acute respiratory syndrome (SARS) and to evaluate the value of these two proteins to be used as diagnostic makers for SARS.
The serum samples of 86 patients with SARS confirmed clinically and serologically, 31 males and 55 females, aged 9 approximately 86, with the course of disease of 1 approximately 81 days, and 745 healthy persons were collected during the course. The specific immunoglobulin G (IgG) against N protein, IgG against S1 domain of S protein, and the SARS-CoV IgG in these sera were detected by ELISA.
The positive rates of anti-N-IgG, anti S1-IgG, and anti-SARS-CoV IgG were 14% (6/44), 5% (2/44), and 14% (6/44) respectively in the first week of the course of disease, 56% (10/18), 39% (7/18), and 56% (10/18) respectively in the second week, and 100% (24/24), S1-IgG 83% (20/24), and 100% (24/24) respectively in the third week. The agreement rates of the results of anti-N-IgG and anti-s1-IgG with that of the anti-SARS-CoV IgG were 88% (76/86) and 83% (71/86) respectively. The anti-SARS-CoV IgG positive rate in the healthy persons was 1.88% (14.745).
The N protein and S1 protein may be used as antigens in the development of serological assay for detection of SARS-CoV infection.
探讨严重急性呼吸综合征（SARS）患者血清中针对核衣壳（N）蛋白和刺突（S）糖蛋白S1结构域的特异性抗体出现规律，评估这两种蛋白作为SARS诊断标志物的价值。
收集86例临床及血清学确诊的SARS患者血清样本，其中男性31例，女性55例，年龄9至86岁，病程1至81天，同时收集745例健康人血清样本。采用酶联免疫吸附测定法（ELISA）检测这些血清中针对N蛋白的特异性免疫球蛋白G（IgG）、针对S蛋白S1结构域的IgG以及抗SARS冠状病毒IgG。
病程第一周，抗N-IgG、抗S1-IgG和抗SARS-CoV IgG的阳性率分别为14%（6/44）、5%（2/44）和14%（6/44）；第二周分别为56%（10/18）、39%（7/18）和56%（10/18）；第三周分别为100%（24/24）、83%（20/24）和100%（24/24）。抗N-IgG和抗S1-IgG结果与抗SARS-CoV IgG结果的符合率分别为88%（76/86）和83%（71/86）。健康人抗SARS-CoV IgG阳性率为1.88%（14/745）。
N蛋白和S1蛋白可作为抗原用于开发检测SARS冠状病毒感染的血清学检测方法。
